ReviewInternal and emergency medicine2016
Why switch from warfarin to NOACs?
Review in Internal and emergency medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.Indian heart journalTrial
- Effect of Danhong injection on pharmacokinetics and pharmacodynamics of rivaroxaban in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Multiorgan Ultrasound for the Diagnosis of Submassive Pulmonary Embolism in a Critically Ill Patient.Cureus · 2025Article
- Direct-Acting Oral Anticoagulant Dabigatran as a Bridging Therapy while Optimizing Warfarin Dosage for Cardioembolic Stroke.Cerebrovascular diseases extra · 2025Article
- Common P-glycoprotein (Biochemia medica · 2024Article
- Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.Journal of thrombosis and thrombolysis · 2021Article
- Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans.Frontiers in pharmacology · 2021Article
- Use of Oral Anticoagulation and Diabetes Do Not Inhibit the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes.Biomedicines · 2020Article
- Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study.British journal of clinical pharmacology · 2020Article
- Optimal Use of the Non-Inferiority Trial Design.Pharmaceutical medicine · 2020Review
- Validation of an algorithm to predict decline in INR following warfarin cessation in patients undergoing invasive procedures.Journal of thrombosis and thrombolysis · 2020Article
- Trends of ambulatory oral anticoagulant prescription in five major cities of China, 2012-2017.BMC health services research · 2020Article
- Hospitalization affects the anticoagulation patterns of patients with atrial fibrillation.Journal of thrombosis and thrombolysis · 2019Article
- Observational
- Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.Vascular health and risk management · 2019Article
- Antithrombotic therapy and intracranial bleeding in subjects with sporadic brain arteriovenous malformations: preliminary results from a retrospective study.Internal and emergency medicine · 2018Article
- NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.Internal and emergency medicine · 2018Article
- Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.Current neurology and neuroscience reports · 2017Review
- Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation.Journal of comparative effectiveness research · 2017Review
- Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation.JRSM cardiovascular diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several patients with non-valvular atrial fibrillation treated with warfarin or other vitamin-K antagonists (VKA) might benefit from switching to an oral non vitamin-K antagonist anticoagulant (NOAC). In the absence of randomised comparative trials of switching to NOACs versus maintaining VKA treatment, several considerations argue in favour of a switching strategy. First, there is conclusive evidence that haemorrhagic strokes and intracranial bleedings are much fewer in number with NOACs than with warfarin. The risk of intracranial bleeding is 52 % lower with NOACS than with warfarin, with extremes ranging from 33 to 70 %. Such benefit is applicable to different NOACs, and independent of the time-in-therapeutic range under warfarin. Patients at increased risk for intra-cranial bleeding (renal dysfunction, or prior stroke or intra-cranial bleeding) should benefit most from switching to NOACs. Patients with labile International Normalized Ratio are also considered good candidates for switching because of their increased risk of stroke, and the lack of interactions between the effects of NOACs versus warfarin and the time-in-therapeutic range. Furthermore, some NOACs proved to be superior to warfarin in reducing the risk of thromboembolic complications even in intention-to-treat analyses. As further advantage, NOACs show fewer drug-drug and drug-food interactions when compared with warfarin. Last, but not least, NOACs do not need frequent blood drawings except in patients with moderate renal dysfunction, in whom periodic controls of serum creatinine are generally advised. The higher cost remains a barrier to a wider use of NOACs, especially in low-income settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.